Treg-dependent immunosuppression triggers effector T cell dysfunction via the STING/ILC2 axis

Kalliopi Domvri1, Savvas Petanidis2, Paul Zarogoulidis3

  • 1Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki 57010, Greece.

Insights

Oncogenic Kras signaling drives regulatory T cells (Tregs) to suppress the immune response in lung cancer, increasing metastasis. Targeting Tregs offers new strategies for inhibiting lung cancer spread, particularly in chemoresistant cases.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Lung cancer is a leading cause of cancer death with low survival rates.
  • Aberrant Kras signaling in the lung tumor microenvironment drives regulatory T cells (Tregs), causing immune deregulation and immunosuppression.
  • The precise pathogenic mechanisms linking Kras, Tregs, and lung cancer progression are not fully understood.

Purpose of the Study:

  • To investigate the role of oncogenic Kras in Treg-mediated immunosuppression within the lung tumor microenvironment.
  • To explore the involvement of Tregs in tumor-associated metabolic reprogramming in lung cancer.
  • To elucidate the mechanisms by which Tregs contribute to lung cancer progression and metastasis.

Main Methods:

  • Investigated the impact of oncogenic Kras on Treg function in the lung tumor microenvironment.
  • Analyzed Treg-associated immunosuppressive pathways, including GATA3/NOS2 and STING inhibition.
  • Assessed the effects of Treg expression on T cell infiltration, effector cell function, and tumor metastasis in vivo.
  • Examined the correlation between Treg phenotypes (TIM3+/LAG3+) and chemoresistance, T cell dysfunction, and CD8 T cell exhaustion.

Main Results:

  • Oncogenic Kras signaling promotes Treg-mediated immunosuppression via GATA3/NOS2 and STING inhibition, reducing CD4+ T cell infiltration and increasing lung metastasis.
  • Enhanced Treg expression is linked to a low T/MDSC ratio and restricted CD8+ T effector cells, fostering a tumor-promoting environment.
  • TIM3+/LAG3+ Tregs contribute to Kras-driven chemoresistance and T cell dysfunction, correlating with CD8 T cell exhaustion and ILC2 augmentation.
  • Increased Treg activity promotes T lymphocyte activation-induced cell death (AICD) and facilitates lymph node metastasis.

Conclusions:

  • Tregs play multifaceted roles in sustaining lung immunosuppressive neoplasia by remodeling the tumor microenvironment.
  • Findings reveal novel Treg-dependent mechanisms driving lung cancer progression, immune evasion, and metastasis.
  • Targeting Treg-mediated immunosuppression presents a promising therapeutic strategy for inhibiting metastasis, especially in chemoresistant lung tumors.